Elevator and Escalator Injury Case Study: Foot Entrapment, Surgery, and Pharmacy Lien

James Wong — Founder & CEO, LienScripts | March 4, 2026 | 8 min read

An escalator entrapment injury at a shopping mall required surgical repair and 10 months of medication management. This case study examines how a pharmacy lien covered the treatment while the premises liability and product liability claims were pursued.

Elevator and escalator injuries are often severe because the mechanical forces involved can cause crush injuries, entrapment injuries, and amputations. Liability typically involves both the property owner (premises liability) and the equipment manufacturer or maintenance company (product liability).

Note: This is a fictionalized case study based on composite facts. Names and identifying details are not real. The clinical details represent typical medication patterns for this injury type.

• Escalator entrapment injuries can involve premises liability against the property owner and product liability against the manufacturer or maintenance company
• Foot and ankle crush injuries from escalator mechanisms require surgical repair and extended wound care with pharmaceutical management
• A 10-month pharmacy lien documented the post-surgical recovery including wound care, pain management, and neuropathic treatment
• LienScripts' MERIT (Medication Evaluation & Rationale for Injury Treatment) report connected the medication regimen to the specific mechanical failure
• Multiple defendants created complex liability dynamics that extended the litigation timeline

Case Background

Patient: Priya K. (name changed), 45-year-old female, retail manager

Incident: Priya was descending an escalator at a large shopping mall. As she approached the bottom, the escalator's comb plate — the metal grating where the steps flatten and passengers step off — had a gap caused by a missing tooth. Her right shoe was caught in the gap, and the escalator's continued motion pulled her right foot into the mechanism. Emergency stop was activated by another shopper approximately 8 seconds after the entrapment began.

Injuries: Crush injury to the right forefoot with fractures of the second, third, and fourth metatarsals, extensive soft tissue degloving of the dorsal foot, laceration of the extensor tendons, and traumatic damage to the dorsal cutaneous nerves.

Initial Treatment: Fire department rescue personnel disassembled a section of the escalator mechanism to free Priya's foot. She was transported to a trauma center where she underwent emergent surgical debridement, open reduction of the metatarsal fractures with K-wire fixation, and primary repair of the extensor tendons. A wound VAC (vacuum-assisted closure) was applied to the degloving wound.

Insurance Situation: Priya had insurance through her employer but the plan had a high deductible and limited formulary coverage. Several post-surgical medications — particularly the wound care agents and neuropathic pain medications — were not covered or required extensive prior authorization.

Attorney: Kenneth W. (name changed), a personal injury attorney with product liability experience.

Legal Context: Multiple Defendants

Kenneth filed claims against three defendants:

The mall owner — premises liability for failure to maintain the escalator in safe operating condition and failure to inspect for comb plate defects.

The escalator maintenance company — negligent maintenance for failure to identify and repair the missing comb plate tooth during scheduled maintenance inspections.

The escalator manufacturer — product liability for a design defect in the comb plate that allowed tooth failure without triggering the emergency stop mechanism.

The Pharmacy Lien: 10 Months of Coverage

Kenneth enrolled Priya in the LienScripts pharmacy lien program at the first post-surgical follow-up. The wound complexity and neuropathic complications required medications that her insurance plan could not provide without significant delays.

Medication Timeline

Acute Post-Surgical Phase: Months 1-2

Oxycodone 10mg every 6 hours for acute post-surgical pain. The crush injury with multiple fractures, soft tissue loss, and tendon repair produced severe pain.

Cephalexin 500mg four times daily for wound infection prophylaxis. Open crush injuries with soil and mechanical contamination carry high infection risk.

Enoxaparin 40mg subcutaneous daily for DVT prophylaxis during the non-weight-bearing period.

Silver sulfadiazine cream applied to the degloving wound site — a topical antimicrobial for open wound management. The pharmacy lien covered this wound care agent, which is often excluded from standard formularies.

Wound Care and Recovery: Months 3-6

Mupirocin 2% ointment replaced silver sulfadiazine as the wound progressed to the granulation phase. The pharmacy record documented the wound healing progression through the changing wound care prescriptions.

Gabapentin 300mg three times daily, titrated to 600mg three times daily for neuropathic pain. The dorsal cutaneous nerve damage from the entrapment produced burning, tingling, and shooting pain across the top of the foot — a classic neuropathic pain pattern.

Celecoxib 200mg daily for anti-inflammatory management as the metatarsal fractures healed and weight-bearing rehabilitation began.

Cyclobenzaprine 10mg at bedtime for the compensatory muscle tension in the calf and lower leg that developed from altered gait mechanics during recovery.

According to James Wong, PharmD, founder of LienScripts, "Escalator entrapment injuries produce some of the most complex wound care and neuropathic pain regimens we manage. The medication record documents not just the pain management but the entire wound healing trajectory — from acute contamination risk through granulation through nerve recovery. Each phase requires different pharmaceutical interventions."

Long-Term Neuropathic Management: Months 7-10

Pregabalin 75mg twice daily was added at month 7 when gabapentin alone was insufficient for the neuropathic foot pain. The dual gabapentinoid approach was documented with clinical rationale from the pain management specialist.

Amitriptyline 25mg at bedtime for adjunctive neuropathic pain management and the insomnia that chronic foot pain was causing.

Topical capsaicin 0.075% cream applied to the dorsal foot for localized neuropathic pain. The topical approach supplemented the systemic gabapentinoid therapy.

By month 10, Priya was ambulatory in custom orthotic footwear. Her podiatrist documented permanent forefoot deformity, chronic neuropathic pain, and a need for lifelong accommodative footwear.

How Pharmacy Documentation Supported the Case

The defense argued that the injury was minor — a "foot scrape" — and that Priya's treatment was excessive. Kenneth used the pharmacy record to refute this:

• The 10-month medication timeline, with wound care agents transitioning through infection prevention, granulation support, and scar management, documented a serious crush injury — not a scrape
• The neuropathic pain medications (gabapentin, pregabalin, amitriptyline) documented nerve damage that simple skin injuries do not produce
• The MERIT report connected each phase of treatment to the specific entrapment mechanism

Settlement Outcome

The case settled with contributions from all three defendants. The pharmaceutical documentation played a central role in establishing injury severity — particularly in countering the defense's attempt to minimize the injury as superficial.

Related Resources

• What Is a MERIT Report?
• Gabapentin for Neuropathic Pain
• Demand Package Pharmacy Records